復星醫藥(02196.HK)：控股子公司Gland Pharma擬在印度證交所和孟買證交所上市
格隆匯11月1日丨復星醫藥(02196.HK)宣佈，於2019年11月1日舉行的會議上已審議並批准建議分拆Gland Pharma並於印度證交所和孟買證交所境外上市的議案。
Gland Pharma於1978年在印度註冊成立。截至公告日期，公司附屬公司Fosun Pharma Industrial Pte. Ltd.、Lustrous Star Limited、Regal Gesture Limited、Ample Up Limited以及復星實業(香港)有限公司持有Gland Pharma合共計約74%的股份。因此，公司間接持有Gland Pharma合共計約74%的股份。Gland Pharma主要從事小分子注射劑仿製藥的開發及生產。
根據上市議案，發行方式包括Gland Pharma境外上市採取公開發行新股和/或現有股東公開發售股份(即存量股轉讓，下同)的方式進行，Gland Pharma境外上市的股份將在印度證交所和孟買證交所公開發售。其中，新增股份規模擬定為不超過Gland Pharma境外上市前其總股本的5%、現有股東公開發售股份規模擬定為不超過Gland Pharma境外上市前其總股本的22.5%。公司擬定轉讓的存量股份數量不超過Gland Pharma境外上市前其總股本的12.5%。
據悉，Gland Pharma的境外上市不會對集團各業務板塊的持續運營運作構成任何實質性影響。一方面，通過Gland Pharma境外上市，有利於Gland Pharma在其本土市場進一步發展壯大，優化其公司治理及資本結構，繼續擴大其行業領先優勢，並有利於提升公司作為控股股東的聲譽和投資回報；另一方面，如果Gland Pharma境外上市成功獲得獨立融資平台，也有助於集團各業務板塊通過公司直接融資更好地獲得發展。因此，Gland Pharma境外上市將會有力促進公司控股戰略的升級，將會進一步鞏固集團的核心競爭力，並促進集團的可持續發展。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app！
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
